EyePoint Pharmaceuticals Inc

NASDAQ: EYPT
$19.74
-$0.20 (-1.0%)
Closing price May 3, 2024

EYPT Chart and Intraday Price

EYPT Company Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry LABORATORY ANALYTICAL INSTRUMENTS
Address 480 PLEASANT STREET, SUITE B300, WATERTOWN, MA, US
Fiscal Year End December
Latest Quarter 9/30/2023
Market Cap 1,367.49M USD
Shares Outstanding 48,838,800
EyePoint Pharmaceuticals, based in Watertown, Massachusetts, focuses on creating treatments for serious retinal diseases. With a strong emphasis on innovation, the company develops drugs that offer sustained release directly into the eye, using its unique Durasert E technology. Its leading candidate, EYP-1901, aims to tackle VEGF-mediated retinal diseases through a novel approach combining a tyrosine kinase inhibitor with sustained delivery technology. EyePoint, originally known as pSivida Corp., rebranded in 2018, continuing its mission to advance eye care.

EYPT Articles

These Biotechs and IPOs Inspire Big Insider Buying
Initial public offerings and a secondary offering inspired insiders to pick up some shares of these biotech companies and others.
Trey Thoelcke
Published:

Insider Buying at These Biotechs Is Huge
As January wound to a close, beneficial owners, executives, and other insiders took advantage of public offerings of stock at these biotech companies.
Trey Thoelcke
Published:

New Year's Insider Buying Focuses on Biotechs
As the year got underway, biotechs were in focus among the notable insider buying, especially in two companies focused on treatments for the eye.
Trey Thoelcke
Published:

Huge Warren Buffett Purchase Highlights Hot Insider Buying
Warren Buffett's Berkshire Hathaway has bolstered its stake in Occidental Petroleum with a huge purchase of shares. Insider buying is heating up in general.
Trey Thoelcke
Published:

What Has Insiders Eyeing This Biotech Stock
A biotech stock rallying on encouraging trial results prompted insider buying and selling. A specialty retailer and others saw insider buying too.
Trey Thoelcke
Published: